IL1B and multiple sclerosis: DMF blocks a final common pathway of inflammasome signalling in vitro, and in keeping with this, DMF treatment normalises serum IL-1β in patients with multiple sclerosis and reduces serum CRP in an animal model of inflammation17,25.